GLP1R and type 2 diabetes mellitus: In Italy, a cost-effectiveness study of liraglutide 1.8 mg versus lixisenatide 20 μg (both are GLP-1 receptor agonists) for treating T2DM patients unable to reach acceptable blood glucose levels on metformin concluded that liraglutide 1.8 mg is likely to be cost-effective versus lixisenatide 20 μg in Italian settings [16].